SCHEMBL1963805

SCHEMBL1963805

Fc1cc(F)c2nc(Cl)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.35
ALDH1A1 P00352 5/20 0.34
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
MAPT P10636 4/20 0.34
RAB9A P51151 3/20 0.34
PKM P14618 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PDE10A Q9Y233 1/20 0.34
HPGD P15428 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2A6 P11509 1/20 0.33
NPC1 O15118 3/20 0.33
HTT P42858 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MCL1 Q07820 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
LMNA P02545 1/20 0.31
AGTR1 P30556 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1964184 0.89 PDE10A (0.30) BACE1PDE10A
SCHEMBL31026244 0.83 BACE1 (0.35) BACE1MEN1KMT2AMAPTCYP1A2
SCHEMBL2170889 0.82 BACE1 (0.36) BACE1ALDH1A1MEN1KMT2AMAPT
SCHEMBL25911523 0.82 ESR1 (0.42)
SCHEMBL20660798 0.79 BACE1 (0.33) BACE1MEN1KMT2AMAPTRAB9A
SCHEMBL31623199 0.77 POLB (0.34) ALDH1A1SMN1; SMN2SLC40A1
SCHEMBL27364124 0.77 FPR2 (0.39) RAB9APDE10ACYP1A2CYP2A6NPC1
SCHEMBL20660716 0.76 CYP11B1 (0.36) BACE1ALDH1A1KMT2AKDM4E
SCHEMBL6088636 0.74 CCR1 (0.52) MEN1KMT2AMAPTRAB9ATDP1
SCHEMBL1963774 0.74 ALDH1A1 (0.34) BACE1ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8987251-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-24 US disclosed
CN-103694163-A Compounds as Potassium Channel Modulators SHANGHAI SIMCERE DRUG RES CO LTD 2014-04-02 CN disclosed
US-20140045817-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-02-13 US disclosed
US-8575145-B2 Triazolopyridine compounds as PIM kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-11-05 US disclosed
EP-2334677-B1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2013-10-09 EP disclosed
CN-102186851-B Triazolopyridine compounds as pim kinase inhibitors ARRAY BIOPHARMA INC 2013-06-12 CN disclosed
CN-102186851-A Triazolopyridine compounds as pim kinase inhibitors ARRAY BIOPHARMA INC 2011-09-14 CN disclosed
US-20110184013-A1 Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors ARRAY BIOPHARMA, INC. 2011-07-28 US disclosed
EP-2334677-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-06-22 EP disclosed
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-16 US disclosed
WO-2010039825-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-04-08 WO disclosed
WO-2010022076-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-02-25 WO disclosed
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC (US) 2009-10-22 US disclosed
EP-1474401-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2004-11-10 EP disclosed
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HIGH POINT PHARMACEUTICALS, LLC 2003-12-25 US disclosed
WO-2003066604-A2 NOVEL ARYL- AND HETEROARYLPIPERAZINES NOVO NORDISK A/S (DK) 2003-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236259-A1 Novel aryl- and heteroarylpiperazines HRH3, HRH2, HRH4 BACE1 3643/4885ALDH1A1 2719/4885MEN1 3565/4885
US-20110144085-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM1, PIM2, PIM3 BACE1 4397/4885ALDH1A1 2440/4885MEN1 3598/4885
US-20140045817-A1 TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS PIM2, PIM1, PIM3 BACE1 4337/4885ALDH1A1 1820/4885MEN1 3710/4885
US-20090264435-A1 Novel Aryl- and Heteroarylpiperazines HRH3, HRH2, HRH4 BACE1 3643/4885ALDH1A1 2719/4885MEN1 3565/4885
US-20110184013-A1 Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors PIM1, PIM2, PIM3 BACE1 4487/4885ALDH1A1 384/4885MEN1 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.